Theseus Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	23.39	179.72	213.92	265.85	224.4
Depreciation & Amortization	26.03	21.88	5.69	0.01	0.02
Other Amortization	15.93	15.89	15.88	22.96	22.22
Loss (Gain) From Sale of Assets	-	-	-266.7	-	-
Loss (Gain) From Sale of Investments	123.41	-88.52	153.29	-89.31	-50.62
Stock-Based Compensation	6.37	5.84	7.35	2.02	1.7
Other Operating Activities	0.48	31.05	65.43	179.16	129.72
Change in Accounts Receivable	-2.29	-20	9.79	-16.78	-14.5
Change in Inventory	-6.81	-12	0.28	-	-
Change in Accounts Payable	-4.59	3.78	0.09	-0.04	0.06
Change in Unearned Revenue	-0.15	-0.82	-0.76	-	-
Change in Income Taxes	41.48	1.73	10.03	-	-
Change in Other Net Operating Assets	-34.58	2.53	-12.57	-0.05	0.13
Operating Cash Flow	188.69	141.06	201.73	363.81	313.11
Operating Cash Flow Growth	33.76%	-30.07%	-44.55%	16.19%	21.62%
Capital Expenditures	-0.27	-0.41	-0.07	-	-0.01
Sale of Property, Plant & Equipment	0.1	-	-	-	-
Cash Acquisitions	-	-	-136.03	-	-
Sale (Purchase) of Intangibles	-4	-	-	-	-
Investment in Securities	-59.62	-66.35	79.47	43.72	-314.92
Investing Cash Flow	-63.79	-66.76	-56.63	43.72	-314.94
Long-Term Debt Issued	-	-	252.54	-	-
Long-Term Debt Repaid	-	-96.2	-165.13	-	-
Net Debt Issued (Repaid)	-	-96.2	87.41	-	-
Issuance of Common Stock	1.47	0.17	0.37	1.17	0.44
Repurchase of Common Stock	-14.92	-75.81	-8.59	-394.21	-0.09
Other Financing Activities	-	-	-134.76	-59.46	-30.13
Financing Cash Flow	-13.45	-171.84	-55.57	-452.5	-29.79
Net Cash Flow	111.45	-97.54	89.52	-44.96	-31.61
Free Cash Flow	188.42	140.65	201.66	363.81	313.1
Free Cash Flow Growth	33.96%	-30.25%	-44.57%	16.20%	21.62%
Free Cash Flow Margin	52.53%	45.30%	60.86%	92.84%	92.97%
Free Cash Flow Per Share	2.54	1.62	2.12	3.86	2.76
Cash Interest Paid	10.36	11.38	11.74	9.93	9.93
Cash Income Tax Paid	11.79	-	53.86	-	-
Levered Free Cash Flow	151.13	123.24	143.42	230.52	199.79
Unlevered Free Cash Flow	162.9	133.15	151.23	233.3	202.85

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q